Dr. Spellberg is chief medical officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center. He is also a professor of clinical medicine and associate dean for clinical affairs at the Keck School of Medicine at USC. He received his BA in molecular cell biology-immunology from UC-Berkeley, attended medical school at UCLA, and completed residency training and his infectious diseases fellowship at Harbor-UCLA Medical Center.
Dr. Spellberg has worked extensively with IDSA to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics. As a member and then co-chair of the IDSA’s Antimicrobial Availability Task Force, he first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development.
Recently he has provided leadership to the global ID community on the themes of ‘Shorter is better’, that ‘Oral is the new IV’, and the development of WikiGuidelines for Infectious Diseases.
The SNAP trial includes all age groups because people of all ages.
A summary of how Staphylococcus aureus and penicillin have been instrumental in both the success and failure of one another since they met. Carly Botheras (PhD Candidate, Geelong Centre for Emerging Infectious Diseases, Barwon Health)
Amy Legg (Clinical Pharmacist) and Prof Marc Scheetz (Professor of Pharmacy and Pharmacology at Midwestern University) explain one of the proposed SNAP substudies involving novel urinary biomarkers.
